IMMULOGIC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Getman who wrote (159)	4/18/1997 9:20:00 PM
From: AgAuUSA	of 305

Paul, Is this what you read? The story is different than you stated....did you read the same report? Could you have made a mistake? Greg biz.yahoo.com Monday February 10 4:08 PM EDT ImmuLogic Reports Fourth Quarter And Year-End 1996 Financial Results "In the first half of 1997 our clinical development program will increase in activity with the planned initiation of an ALLERVAX CAT catroom trial, a multiple sclerosis phase I trial, the filing of an IND and initiation of a phase I trial for the cocaine vaccine, and an ALLERVAX RAGWEED trial to be initiated in July prior to the start of the next ragweed season," said Joseph Marr, M.D. acting President and Chief Executive Officer of ImmuLogic Pharmaceutical Corporation.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next